Author: Rothlin, Rodolfo Pedro; Duarte, Mariano; Pelorosso, Facundo Germán; Nicolosi, Liliana; Salgado, M. Victoria; Vetulli, Héctor Miguel; Spitzer, Eduardo
Title: Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical Trials Cord-id: ku7q3rt1 Document date: 2021_3_29
ID: ku7q3rt1
Snippet: COVID-19 pandemic demands a swift response to find therapeutic tools that effectively reduce morbidity and mortality. Despite initial fears, evidence from retrospective observational studies supports the inhibition of the renin-angiotensin system as an emerging pathway to delay or moderate angiotensin II-driven lung inflammation. This has triggered several prospective clinical trials. In this commentary we provide an overview and analysis of current ongoing clinical trials aimed at evaluating th
Document: COVID-19 pandemic demands a swift response to find therapeutic tools that effectively reduce morbidity and mortality. Despite initial fears, evidence from retrospective observational studies supports the inhibition of the renin-angiotensin system as an emerging pathway to delay or moderate angiotensin II-driven lung inflammation. This has triggered several prospective clinical trials. In this commentary we provide an overview and analysis of current ongoing clinical trials aimed at evaluating the therapeutic efficacy of angiotensin receptor blocker (ARB) use in COVID-19. The relevance of the results of these trials will have to be interpreted depending on the stage and severity of the disease and in light of the start time of their prescription related to the time of diagnosis of COVID-19 as well as the administered doses.
Search related documents:
Co phrase search for related documents- ace enzyme and aceis arbs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- ace enzyme and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
- ace enzyme and acute lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
- ace enzyme and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- ace enzyme and adipose tissue: 1, 2, 3, 4, 5, 6, 7
- ace enzyme and adrenal gland: 1
- ace enzyme and local tissue ras: 1, 2
- ace enzyme and long term short term: 1, 2
- ace enzyme and lung failure: 1, 2, 3, 4, 5, 6, 7, 8
- ace enzyme and lung failure severity: 1
- ace enzyme and lung function: 1, 2, 3, 4, 5, 6
- ace enzyme and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51
- ace enzyme and lung involvement: 1, 2, 3
- ace enzyme angiotensin convert and acute respiratory syndrome: 1
Co phrase search for related documents, hyperlinks ordered by date